A Phase 2 interventional study of Meningococcal B vaccine and Meningococcal B vaccine in Meningococcal Meningitis and Meningococcal Infections, sponsored by Novartis Vaccines. Completed at 38 sites in 5 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-07.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 2nd largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 2nd registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:
University Ghent · Sites in Belgium
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 55 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,507 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 250 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
32 studies in Meningitis, Meningococcal by Novartis: none open now, none under way, none of them phase 3. Of 32 finished, 28 (88%) have results posted.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 7th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2009, is one of 8 in phase 2, and was the 12th registered.
Novartis’s Meningitis, Meningococcal studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Meningitis, Meningococcal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any impairment/alteration of the immune system resulting from (for example):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccine candidate formulation I
Biological: Meningococcal B vaccine
Vaccine candidate formulation II
Biological: Meningococcal B vaccine
Vaccine candidate formulation III
Biological: Meningococcal B vaccine
Vaccine candidate formulation IV
Biological: Meningococcal B vaccine
Vaccine candidate formulation V
Biological: Meningococcal B vaccine
Vaccine candidate formulation VI
Biological: Meningococcal B vaccine
Control
Biological: Control
Vaccine candidate formulation I with antipyretic
Biological: Meningococcal B vaccine with antipyretic
Vaccine candidate formulation I
Vaccine candidate formulation II
Vaccine candidate formulation III
Vaccine candidate formulation IV
Vaccine candidate formulation V
Vaccine candidate formulation VI
Control
Drug pages: 4CMenB vaccine · Antipyretics
Vaccine candidate formulation I with antipyretic
Percentages of Subjects With Serum Bactericidal Activity (hSBA) ≥ 1:5 at 1 Month After Third Vaccination
To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.
Time frame: At baseline (pre-vaccination) and 30 days after the third vaccination.
Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination
To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever \>=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.
Time frame: Day 1 to day 3 after first vaccination.
Geometric Mean Bactericidal Titers (GMTs), One Month After Third and Booster Vaccination (Men B at 12 Months of Age)
ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at: 1. One month after third vaccination. 2. One month after booster vaccination (Men B at 12 months of age).
Time frame: At baseline (pre-vaccination), 30 days after the third vaccination, at booster Baseline and at booster vaccination (12 months of age)
Geometric Mean Bactericidal Titers,One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)
To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.
Time frame: At Baseline (pre-vaccination), at 30 days after the third vaccination, at booster Baseline, at 30 days
Geometric Mean Ratios, One Month After Primary and Booster Vaccination (Men B at 12 Months of Age)
To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).
Time frame: After the third and the booster vaccination.
Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (Pre-fourth Dose)
To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.
Time frame: 12 months (pre-fourth vaccination)
Percentage of Subjects With hSBA≥1:5, Persistence of Bactericidal Antibodies at 12 Months of Age (One Month-post Fourth Dose)
To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.
Time frame: 1 month after fourth vaccination
Geometric Mean Bactericidal Titers, After Primary and Booster Vaccinations (Men B at 12 Months of Age)
To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.
Time frame: At 13 months
Percentage of Subjects With hSBA ≥1:5, First Dose of Meningococcal B Vaccine (One Month After Booster)
To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).
Time frame: 1 month after booster
Safety and Reactogenicity of Study Vaccines Within 7 Days After Second and Third Vaccination
To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).
Time frame: Day 1 through day 7 after second and third vaccination.
Number of Subjects With Solicited Local Reactions Within 7 Days (Day 1-7) After Each Vaccination
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.
Time frame: Day 1 through day 7 after each vaccination.
Number of Subjects With Solicited Systemic Reactions Within 7 Days (Day 1-7) After Each Vaccination
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.
Time frame: Day 1 through day 7 after each vaccination.
Number of Subjects With Unsolicited Adverse Events Within 7 Days (Day 1-7) After Each Vaccination
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.
Time frame: Day 1 through day 7 after each vaccination.
Number of Subjects With Severe Adverse Events and Adverse Events Necessitating a Medical Office or Emergency Room (ER) Visit and/or Resulting in Premature Withdrawal of the Subject From the Study, Throughout the Study Period.
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.
Time frame: Overall study period.
Number of Subjects With Local and Systemic Reactions Within 7 Days (Day 1-7) After Second rMenB+OMV NZ Vaccination in MenC Group
To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.
Time frame: Day 1 through day 7 at 13 months age.
| Milestone | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Started | 188 | 190 | 192 | 188 | 191 | 188 | 186 | 184 |
| Premature withdrawal | 3 | 5 | 6 | 1 | 3 | 1 | 5 | 1 |
| Completed | 185 | 185 | 186 | 187 | 188 | 187 | 181 | 183 |
| Not completed | 3 | 5 | 6 | 1 | 3 | 1 | 5 | 1 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Inappropriate enrollment | 0 | 4 | 0 | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Started | 155 | 163 | 169 | 170 | 168 | 165 | 165 | 161 |
| Premature withdrawal | 3 | 2 | 5 | 3 | 5 | 5 | 5 | 2 |
| Completed | 152 | 161 | 164 | 167 | 163 | 160 | 160 | 159 |
| Not completed | 3 | 2 | 5 | 3 | 5 | 5 | 5 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 | 4 | 2 | 4 | 4 | 3 | 0 |
| Withdrew: Administrative reason | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
To assess the immunogenicity of seven different formulations of 4CMenB (groups I-VI and VIII) given to healthy infants at 2,3 and 4 months of age as measured by percentages of subjects with serum bactericidal activity (SBA) titer≥1:5 against 44/76-SL, 5/99 and NZ98/254 reference strains, at 1 month after the third vaccination.. The analysis was done on the Per Protocol Primary Population at one month after third injection.
| Percentages of Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| 44/76SLBaseline(N=166,171,168,170,169,168,168,166) | 5 (2 to 9) | 2 (0 to 5) | 4 (1 to 8) | 4 (2 to 8) | 4 (2 to 8) | 4 (2 to 8) | 2 (1 to 6) | 3 (1 to 7) |
| 44/76-SL > 3rd(N=170,170,166,166,169,167,165,167) | 100 (98 to 100) | 99 (97 to 100) | 99 (97 to 100) | 100 (98 to 100) | 99 (97 to 100) | 99 (96 to 100) | 6 (3 to 11) | 100 (98 to 100) |
| 5/99-Baseline (N=162,162,161,161,166,166,161,157) | 5 (2 to 9) | 3 (1 to 7) | 6 (3 to 10) | 4 (2 to 9) | 8 (5 to 14) | 4 (2 to 8) | 6 (3 to 10) | 4 (1 to 8) |
| 5/99 > 3rd (N=165,167,161,166,165,161,159,160) | 99 (97 to 100) | 100 (98 to 100) | 99 (97 to 100) | 100 (98 to 100) | 100 (98 to 100) | 99 (97 to 100) | 3 (1 to 7) | 99 (97 to 100) |
| NZ98/254Baseline(N=170,174,171,174,171,173,171,169 | 1 (0.015 to 3) | 0 (0 to 2) | 1 (0.015 to 3) | 1 (0.015 to 3) | 1 (0 to 4) | 1 (0 to 4) | 2 (0 to 5) | 1 (0.015 to 3) |
| NZ98/254 > 3rd (N=171,172,169,168,172,169,168,168) | 78 (71 to 84) | 67 (59 to 74) | 56 (48 to 64) | 1 (0.015 to 3) | 62 (54 to 69) | 81 (74 to 87) | 2 (0 to 5) | 74 (67 to 81) |
ToTo assess the immune response of seven different formulations of meningococcal multi-component recombinant, adsorbed vaccine (rMenB+OMV NZ or rMenB (no OMV)) in healthy toddlers as measured by SBA geometric mean titers (GMTs) at: 1. One month after third vaccination. 2. One month after booster vaccination (Men B at 12 months of age).
| Titers | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL Base(N=166,171,168,170,169,168,168,166) | 1.25 (1.14 to 1.37) | 1.12 (1.03 to 1.23) | 1.2 (1.1 to 1.32) | 1.19 (1.08 to 1.3) | 1.31 (1.19 to 1.43) | 1.2 (1.09 to 1.31) | 1.16 (1.09 to 1.25) | 1.18 (1.08 to 1.3) |
| 44/76-SL > 3(N=170,170,166,166,169,167,165,167) | 101 (90 to 113) | 112 (101 to 126) | 113 (101 to 126) | 62 (56 to 70) | 71 (64 to 80) | 102 (92 to 114) | 1.24 (1.11 to 1.39) | 102 (91 to 115) |
| 44/76-SL - Base Boost(N=69,78,74,78,71,71,74,70) | 4.94 (3.76 to 6.5) | 5.22 (4.03 to 6.76) | 5.72 (4.41 to 7.42) | 5.44 (4.19 to 7.06) | 3.96 (3.02 to 5.18) | 3.76 (2.87 to 4.94) | 1.15 (1.03 to 1.29) | 4.51 (3.43 to 5.95) |
| 44/76-SL > Boost(N=65,73,70,75,76,71,75,63) | 120 (95 to 150) | 152 (122 to 189) | 118 (95 to 146) | 53 (43 to 66) | 99 (79 to 122) | 105 (84 to 131) | 12 (10 to 16) | 136 (107 to 172) |
| 5/99-Baseline-(N=162,162,161,161,166,166,161,157) | 1.18 (1.07 to 1.3) | 1.09 (0.99 to 1.2) | 1.12 (1.02 to 1.23) | 1.13 (1.03 to 1.25) | 1.3 (1.18 to 1.43) | 1.16 (1.05 to 1.27) | 1.21 (1.09 to 1.34) | 1.07 (0.97 to 1.18) |
| 5/99 > 3 (N=165,167,161,166,165,161,160) | 396 (348 to 450) | 503 (442 to 572) | 534 (469 to 608) | 389 (342 to 443) | 316 (278 to 360) | 371 (326 to 422) | 1.15 (1.03 to 1.29) | 455 (399 to 519) |
| 5/99 Base Boost(N=71,76,80,72,77,78,70,71) | 69 (53 to 88) | 91 (71 to 116) | 111 (87 to 141) | 74 (57 to 94) | 54 (42 to 68) | 64 (50 to 81) | 1.11 (0.95 to 1.29) | 106 (82 to 136) |
| 5/99 > Boost(N=73,77,79,72,76,74,69,76) | 1950 (1573 to 2417) | 1819 (1478 to 2238) | 2238 (1820 to 2751) | 730 (590 to 903) | 983 (801 to 1205) | 1321 (1074 to 1624) | 41 (29 to 57) | 2182 (1769 to 2691) |
| NZ98/254-BaselineN=170,174,171,174,171,173,171,169 | 1.02 (0.99 to 1.06) | 1.02 (0.99 to 1.05) | 1.03 (1 to 1.06) | 1.04 (1 to 1.07) | 1.03 (1 to 1.06) | 1.04 (1.01 to 1.08) | 1.06 (1 to 1.13) | 1.02 (0.99 to 1.05) |
| 1month after 3rd vaccN=171,172,169,172,169,169,168 | 10 (8.59 to 12) | 7.81 (6.69 to 9.12) | 5.74 (4.92 to 6.71) | 1.05 (0.9 to 1.23) | 6.66 (5.71 to 7.77) | 11 (9.16 to 13) | 1.05 (1.01 to 1.1) | 8.48 (7.24 to 9.93) |
| NZ98/254 Bas Bst N=141,155,155,150,150,153,148,143 | 1.6 (1.43 to 1.8) | 1.28 (1.15 to 1.43) | 1.23 (1.1 to 1.37) | 1.11 (0.99 to 1.24) | 1.35 (1.21 to 1.5) | 1.41 (1.26 to 1.57) | 1.03 (1 to 1.06) | 1.48 (1.32 to 1.66) |
| 1month after boosterN=138,152,150,149,152,146,140 | 20 (16 to 24) | 18 (15 to 22) | 11 (9.07 to 13) | 1.67 (1.38 to 2.03) | 14 (12 to 17) | 20 (16 to 24) | 2.2 (1.89 to 2.57) | 20 (17 to 25) |
To compare the antibody response of meningococcal multi-component recombinant, adsorbed vaccine (formulation I vs. formulation VIII) and of routine infant vaccine given with or without prophylactic administration of paracetamol medication in healthy toddlers.
| Titers | B+OMV (Group I) | Par+B+OMV (Group VIII) |
|---|---|---|
| 44/76-SL Strain - Baseline (N=166,166) | 1.25 (1.14 to 1.37) | 1.18 (1.08 to 1.3) |
| 44/76-SL > 3rd (N=170,167) | 101 (90 to 113) | 102 (91 to 115) |
| 44/76-SL Baseline booster (N=69,70) | 4.94 (3.76 to 6.5) | 4.51 (3.43 to 5.95) |
| 44/76-SL > booster (N=65,63) | 120 (95 to 150) | 136 (107 to 172) |
| 5/99 Strain - Baseline (N=162,157) | 1.18 (1.07 to 1.3) | 1.07 (0.97 to 1.18) |
| 5/99 > 3rd (N=165,160) | 396 (348 to 450) | 455 (399 to 519) |
| 5/99 Baseline booster (N=71,71) | 69 (53 to 88) | 106 (82 to 136) |
| 5/99 > booser (N=73,76) | 1950 (1573 to 2417) | 2182 (1769 to 2691) |
| NZ98/254 Strain-Baseline (N=170,169) | 1.02 (0.99 to 1.06) | 1.02 (0.99 to 1.05) |
| NZ98/254 > 3rd (N=171,168) | 10 (8.59 to 12) | 8.48 (7.24 to 9.93) |
| NZ98/254 Baseline booster (N=141,143) | 1.6 (1.43 to 1.8) | 1.48 (1.32 to 1.66) |
| NZ98/254 > booster (N= 138, 140) | 20 (16 to 24) | 20 (17 to 25) |
To compare the antibody response between meningococcal multi-component recombinant adsorbed vaccine (formulation I) and routine infant vaccine group along with meningococcal multi-component recombinant adsorbed vaccine with prophylactic administration of paracetamol medication as measured by Geometric Mean Ratios (GMRs).
| Ratios | B+OMV (Group I) | Par+B+OMV (Group VIII) |
|---|---|---|
| 44/76-SL > 3rd (N=157,157) | 80 (69 to 93) | 84 (72 to 97) |
| 44/76-SL > Booster (N=59,56) | 24 (18 to 31) | 28 (21 to 36) |
| 5/99 > 3rd (N=152,142) | 345 (292 to 408) | 417 (350 to 497) |
| 5/99 > Booster (N=68,68) | 27 (21 to 35) | 20 (16 to 25) |
| NZ98/254 > 3rd (N=162,160) | 9.65 (8.19 to 11) | 8.69 (7.36 to 10) |
| NZ98/254 > Booster (N=129,127) | 12 (10 to 15) | 14 (11 to 17) |
To assess the persistence of bactericidal antibodies at 12 months of age after primary vaccination - three doses of one of the seven different formulations of rMenB+OMV NZ or rMenB (no OMV) (Group I-VI and VIII) and rMenB+OMV NZ with paracetamol medication.
| Percentages of Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL Pre-Boost(N=69,78,74,78,71,71,74,70) | 55 (43 to 67) | 58 (46 to 69) | 66 (54 to 77) | 63 (51 to 74) | 45 (33 to 57) | 44 (32 to 56) | 4 (1 to 11) | 47 (35 to 59) |
| 5/99 Pre-Boost(N=71,76,80,72,77,78,70,71) | 97 (90 to 100) | 100 (95 to 100) | 100 (95 to 100) | 97 (90 to 100) | 97 (91 to 100) | 99 (93 to 100) | 1 (0.036 to 8) | 100 (95 to 100) |
| NZ98/254 Pre-B(N=141,155,155,150,150,153,148,143) | 12 (7 to 19) | 6 (3 to 11) | 5 (2 to 10) | 3 (1 to 7) | 7 (3 to 12) | 8 (4 to 13) | 0 (0 to 2) | 11 (7 to 18) |
To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (groups I-VI and VIII) induced sufficient immune response when given to healthy toddlers at 12 months of age, as measured by percentage of subjects with SBA titer ≥ 1:5, at 1 month after the fourth vaccination.
| Percentages of Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL > Booster(N=65,73,70,75,76,71,63) | 100 (94 to 100) | 100 (95 to 100) | 100 (95 to 100) | 97 (91 to 100) | 100 (95 to 100) | 99 (92 to 100) | 84 (74 to 91) | 100 (94 to 100) |
| 5/99 strain (N=73,77,79,72,76,74,76) | 100 (95 to 100) | 100 (95 to 100) | 100 (95 to 100) | 100 (95 to 100) | 100 (95 to 100) | 100 (95 to 100) | 93 (84 to 98) | 100 (95 to 100) |
| NZ98/254 (N=138,152,150,149,152,146,147,140) | 89 (83 to 94) | 89 (83 to 93) | 78 (71 to 84) | 18 (12 to 25) | 83 (76 to 89) | 88 (82 to 93) | 24 (18 to 32) | 90 (84 to 94) |
To assess the induction of immunological memory of three doses of meningococcal multi-component recombinant, adsorbed vaccine by comparing the serum bactericidal antibodies Geometric Mean Bactericidal Titers (GMTs) response in healthy toddlers administered the fourth dose at 12 months of age to the response in meningococcal B vaccine naive toddlers (Group VII) receiving the first dose of meningococcal multi-component recombinant, adsorbed vaccine at 12 months of age.
| Titers | B+OMV (Group I) | MenC (Group VII) |
|---|---|---|
| 44/76-SL > Booster (N=65,75) | 120 (95 to 150) | 12 (10 to 16) |
| 5/99 > Booster (N=73,69) | 1950 (1573 to 2417) | 41 (29 to 57) |
| NZ98/254 > Booster | 20 (16 to 24) | 2.2 (1.89 to 2.57) |
To assess the immune response of first dose of meningococcal multi-component recombinant, adsorbed vaccine given at 12 months of age to toddlers who previously received three doses of MenC-CRM197 vaccine as infants (group VII).
| Percentage of Subjects | MenC (Group VII) |
|---|---|
| 44/76-SL > Booster (N=75) | 84 (74 to 91) |
| 5/99 > Booster (N=69) | 93 (84 to 98) |
| NZ98/254 > Booster | 24 (18 to 32) |
To assess if any of six different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (Group II to VI, Group VIII) reduced the incidence of fever ≥ 38.5ºC (rectal) occurring within 3 days (day 1-3) following second and third vaccination and 7 days (day 1-7) following each vaccination as compared to rMenB+OMV NZ (Group I).
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Second Vaccination (day1-3) | 90 | 82 | 76 | 35 | 74 | 89 | 30 | 33 |
| 3rd vac d 1-3(N=181,179,185,183,181,180,177,179) | 55 | 50 | 36 | 15 | 40 | 53 | 12 | 20 |
| First Vaccination (day1-7) | 94 | 91 | 74 | 24 | 60 | 76 | 22 | 46 |
| Second Vaccination (day 1-7) | 90 | 82 | 77 | 36 | 74 | 90 | 30 | 35 |
| 3rd vac d 1-7(N=181,179,185,183,181,180,177,179) | 55 | 53 | 38 | 16 | 42 | 54 | 14 | 20 |
| Booster d 1-7(N=155,162,169,168,168,165,164,159) | 81 | 86 | 64 | 43 | 78 | 68 | 84 | 58 |
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited local reactions within 7 days (day 1-7) after each vaccination.
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Any Local (First Vacc) | 163 | 155 | 153 | 123 | 141 | 157 | 127 | 137 |
| Injection Site Tenderness (First Vacc) | 114 | 116 | 111 | 54 | 97 | 121 | 48 | 79 |
| Injection Site Erythema (First Vacc) | 108 | 99 | 94 | 53 | 77 | 106 | 45 | 73 |
| Injection Site Induration (First Vacc) | 101 | 98 | 85 | 48 | 86 | 84 | 25 | 82 |
| Injection Site Swelling (First Vacc) | 58 | 49 | 55 | 24 | 48 | 60 | 15 | 41 |
| Any Local (Second Vacc) | 156 | 156 | 155 | 126 | 132 | 156 | 118 | 140 |
| Injection Site Tenderness (Second Vacc) | 121 | 116 | 97 | 48 | 88 | 116 | 47 | 85 |
| Injection Site Erythema (Second Vacc) | 104 | 114 | 114 | 71 | 90 | 104 | 44 | 94 |
| Injection Site Induration (Second Vacc) | 103 | 105 | 97 | 63 | 83 | 94 | 38 | 79 |
| Injection Site Swelling (Second Vacc) | 64 | 61 | 54 | 34 | 50 | 58 | 21 | 52 |
| Any Local (3rd N=181,179,185,183,181,180,177,179) | 151 | 147 | 141 | 122 | 130 | 152 | 113 | 128 |
| Injection Site Tenderness (Third Vacc) | 102 | 98 | 78 | 47 | 77 | 111 | 42 | 66 |
| Injection Site Erythema (Third Vacc) | 110 | 106 | 112 | 72 | 94 | 101 | 63 | 91 |
| Injection Site Induration (Third Vacc) | 97 | 92 | 92 | 62 | 79 | 89 | 55 | 80 |
| Injection Site Swelling (Third Vacc) | 56 | 56 | 46 | 35 | 45 | 58 | 29 | 47 |
| Any Local BoostN=155,162,169,168,168,165,162,159 | 131 | 132 | 149 | 113 | 127 | 130 | 133 | 121 |
| Injection Site Tenderness (Booster Vacc) | 116 | 107 | 120 | 77 | 106 | 112 | 108 | 92 |
| Injection Site Erythema (Booster Vacc) | 90 | 101 | 116 | 67 | 80 | 85 | 93 | 81 |
| Injection Site Induration (Booster Vacc) | 73 | 83 | 95 | 56 | 66 | 73 | 62 | 60 |
| Injection Site Swelling (Booster Vacc) | 55 | 59 | 69 | 31 | 47 | 52 | 39 | 47 |
To assess if any of six different formulations of vaccine groups (Group II to Group VI, Group VIII) reduced the incidence of fever \>=38.5C (rectal) occurring within three days (day 1-day3) following first vaccination. The analysis was done on the Safety Population.
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Fever ≥ 38.5 °C (Rectal Temperature) Within 3 Days (Day 1-3) After First Vaccination | 94 | 91 | 74 | 24 | 60 | 76 | 21 | 46 |
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting solicited systemic reactions within 7 days (day 1-7) after each vaccination.
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Any Systemic (First Vacc) | 167 | 173 | 175 | 152 | 162 | 171 | 136 | 150 |
| Change Eat. Habits (First Vacc) | 76 | 87 | 84 | 52 | 84 | 90 | 41 | 66 |
| Sleepiness (First Vacc) | 120 | 131 | 119 | 96 | 117 | 119 | 92 | 116 |
| Vomiting (First Vacc) | 24 | 18 | 25 | 15 | 22 | 26 | 17 | 22 |
| Diarrhea (First Vacc) | 57 | 55 | 54 | 31 | 41 | 49 | 45 | 41 |
| Irritability (First Vacc) | 128 | 124 | 128 | 99 | 131 | 131 | 79 | 97 |
| Unus Crying (First Vacc) | 95 | 101 | 105 | 61 | 96 | 108 | 63 | 74 |
| Rash (First Vacc) | 6 | 5 | 5 | 7 | 10 | 10 | 4 | 5 |
| Fever ( ≥ 38.5°C ) (First Vacc) | 94 | 91 | 74 | 24 | 60 | 76 | 22 | 46 |
| Antipyr. Med. Used (First Vacc) | 102 | 94 | 92 | 37 | 74 | 95 | 32 | 166 |
| Any Systemic (Second Vacc) | 168 | 158 | 166 | 144 | 156 | 158 | 126 | 147 |
| Change Eat. Habits (Second Vacc) | 62 | 55 | 58 | 53 | 60 | 80 | 33 | 54 |
| Sleepiness (Second Vacc) | 105 | 100 | 102 | 85 | 92 | 109 | 75 | 84 |
| Vomiting (Second Vacc) | 18 | 18 | 14 | 15 | 17 | 20 | 14 | 20 |
| Diarrhea (Second Vacc) | 43 | 41 | 47 | 40 | 39 | 47 | 39 | 40 |
| Irritability (Second Vacc) | 130 | 121 | 124 | 94 | 117 | 126 | 82 | 99 |
| Unus Crying (Second Vacc) | 90 | 90 | 84 | 70 | 83 | 99 | 45 | 71 |
| Rash (Second Vacc) | 4 | 9 | 4 | 5 | 7 | 4 | 5 | 5 |
| Fever ( ≥ 38.5°C ) (Second Vacc) | 90 | 82 | 77 | 36 | 74 | 90 | 30 | 35 |
| Antipyr. Med. Used (Second Vacc) | 100 | 94 | 83 | 40 | 79 | 105 | 39 | 163 |
| Any Syst (3rdN=181,179,185,182,181,180,177,179) | 146 | 131 | 132 | 122 | 141 | 151 | 106 | 127 |
| Change Eat. Habits (Third Vacc) | 49 | 50 | 42 | 37 | 45 | 60 | 22 | 48 |
| Sleepiness (Third Vacc) | 75 | 67 | 82 | 64 | 77 | 79 | 52 | 75 |
| Vomiting (Third Vacc) | 8 | 18 | 15 | 12 | 12 | 13 | 11 | 20 |
| Diarrhea (Third Vacc) | 33 | 29 | 39 | 31 | 34 | 40 | 19 | 32 |
| Irritability (Third Vacc) | 115 | 97 | 93 | 74 | 104 | 115 | 76 | 84 |
| Unus Crying (Third Vacc) | 76 | 82 | 62 | 47 | 69 | 100 | 38 | 47 |
| Rash (Third Vacc) | 1 | 6 | 4 | 2 | 8 | 10 | 6 | 6 |
| Fever ( ≥ 38.5°C ) (Third Vacc) | 55 | 53 | 38 | 16 | 42 | 54 | 14 | 20 |
| Antipyr. Med. Used (Third Vacc) | 66 | 60 | 51 | 26 | 49 | 63 | 20 | 153 |
| Any Syst(BoosterN=155,162,169,169,168,165,164,159) | 143 | 144 | 139 | 118 | 141 | 142 | 142 | 137 |
| Change Eat. Habits (Booster Vacc) | 74 | 77 | 79 | 52 | 70 | 80 | 59 | 66 |
| Sleepiness (Booster Vacc) | 76 | 90 | 90 | 63 | 86 | 88 | 85 | 80 |
| Vomiting (Booster Vacc) | 6 | 11 | 7 | 7 | 10 | 9 | 9 | 20 |
| Diarrhea (Booster Vacc) | 30 | 34 | 36 | 43 | 32 | 30 | 26 | 30 |
| Irritability (Booster Vacc) | 116 | 111 | 112 | 86 | 116 | 115 | 117 | 96 |
| Unus Crying (Booster Vacc) | 74 | 64 | 69 | 46 | 71 | 82 | 73 | 50 |
| Rash (Booster Vacc) | 5 | 5 | 8 | 2 | 8 | 4 | 6 | 5 |
| Fever ( ≥ 38.5°C ) (Booster Vacc) | 81 | 86 | 64 | 43 | 78 | 68 | 84 | 58 |
| Antipyr. Med. Used (Booster Vacc) | 84 | 82 | 83 | 42 | 75 | 80 | 92 | 128 |
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting unsolicited Adverse Events (AEs), serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal (throughout the study period) within 7 days (day 1-7) after each vaccination.
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| Any AE (Day 1 to 7) (First Vacc) | 55 | 52 | 51 | 33 | 35 | 39 | 27 | 42 |
| At least Possibly related AE (First Vacc) | 48 | 48 | 43 | 30 | 27 | 34 | 22 | 36 |
| Any SAE (First Vacc) | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Any AE D1-7 2nd N=182,181,186,184,183,180,178,180 | 55 | 53 | 50 | 41 | 36 | 47 | 28 | 45 |
| At least Possibly related AE (Second Vaccination) | 49 | 45 | 45 | 36 | 33 | 41 | 26 | 39 |
| Any SAE (Second Vacc) | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Any AE D1-7 3rd N=182,181,186,184,182,180,177,179 | 40 | 59 | 49 | 35 | 31 | 45 | 35 | 39 |
| At least Possibly related AE (Third Vacc) | 34 | 52 | 45 | 29 | 23 | 37 | 29 | 36 |
| Any SAE (Third Vacc) | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Any AE D 1-7Boos N=155,163,169,169,168,165,165,161 | 35 | 46 | 56 | 35 | 29 | 30 | 37 | 30 |
| At least Possibly related AE (Booster Vacc) | 28 | 41 | 48 | 23 | 23 | 26 | 30 | 25 |
| Any SAE (Booster Vacc) | 0 | 1 | 2 | 0 | 3 | 0 | 0 | 0 |
To assess the safety and tolerability of each of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine (group I to VI, group VIII) in terms of number of subjects reporting Severe Adverse Events (SAEs) and Adverse Events (AEs) necessitating a medical office or Emergency Room (ER) visit and/or resulting in premature withdrawal of the subject from the study, throughout the study period.
| Subjects | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) |
|---|---|---|---|---|---|---|---|---|
| AE Leading to Premature Withdrawal-Primary Vacc | 0 | 2 | 2 | 0 | 0 | 1 | 2 | 1 |
| Treatment Emergent SAEs - Primary Vacc | 16 | 20 | 12 | 20 | 13 | 16 | 11 | 15 |
| Tr E SAE Boost (N=155,163,169,169,168,165,165,161) | 14 | 7 | 12 | 5 | 15 | 9 | 9 | 16 |
To assess the safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group VII) given at 12 and 13 months of age to toddlers who previously received three doses of Menjugate as infants.
| Subjects | MenC (Group VII) |
|---|---|
| Injection Site Tenderness | 92 |
| Injection Site Erythema | 84 |
| Injection Site Induration | 59 |
| Injection Site Swelling | 35 |
| Change Eat. Habits (N=155) | 43 |
| Sleepiness | 57 |
| Vomiting | 8 |
| Diarrhea | 18 |
| Irritability | 75 |
| Unus Crying | 37 |
| Rash | 4 |
| Fever ( ≥ 38.5°C ) (N=158) | 35 |
| Antipyr. Med. Used (N=157) | 47 |
Collected over All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; serious adverse events (SAEs), medically attended AEs, AEs leading to premature withdrawal were collected during the overall study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B+OMV (Group I) | — | 16/184 (8.7%) | 181/184 (98.4%) |
| B+½ OMV (Group II) | — | 20/184 (10.9%) | 183/184 (99.5%) |
| B+1/4 OMV (Group III) | — | 12/189 (6.3%) | 186/189 (98.4%) |
| B (Group IV) | — | 20/187 (10.7%) | 183/187 (97.9%) |
| ½ (B+OMV) (Group V) | — | 13/187 (7%) | 180/187 (96.3%) |
| PH2 B+OMV (Group VI) | — | 16/185 (8.6%) | 180/185 (97.3%) |
| MenC (Group VII) | — | 11/184 (6%) | 175/184 (95.1%) |
| Par+B+OMV (Group VIII) | — | 15/183 (8.2%) | 175/183 (95.6%) |
| B+OMV (Group I) Booster Phase | — | 14/155 (9%) | 151/155 (97.4%) |
| B+½ OMV (Group II) Booster Phase | — | 7/163 (4.3%) | 159/163 (97.5%) |
| B+1/4 OMV (Group III) Booster Phase | — | 12/169 (7.1%) | 162/169 (95.9%) |
| B (Group IV) Booster Phase | — | 5/169 (3%) | 152/169 (89.9%) |
| ½ (B+OMV) (Group V) Booster Phase | — | 15/168 (8.9%) | 154/168 (91.7%) |
| PH2 B+OMV (Group VI) Booster Phase | — | 9/165 (5.5%) | 156/165 (94.5%) |
| MenC (Group VII) Booster Phase | — | 9/165 (5.5%) | 155/165 (93.9%) |
| Par+B+OMV (Group VIII) Booster Phase | — | 14/161 (8.7%) | 150/161 (93.2%) |
| Event | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) | B+OMV (Group I) Booster Phase | B+½ OMV (Group II) Booster Phase | B+1/4 OMV (Group III) Booster Phase | B (Group IV) Booster Phase | ½ (B+OMV) (Group V) Booster Phase | PH2 B+OMV (Group VI) Booster Phase | MenC (Group VII) Booster Phase | Par+B+OMV (Group VIII) Booster Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/184 | 2/184 | 1/189 | 3/187 | 1/187 | 3/185 | 1/184 | 1/183 | 2/155 | 2/163 | 1/169 | 1/169 | 1/168 | 5/165 | 0/165 | 3/161 |
| BronchitisInfections and infestations | 3/184 | 2/184 | 4/189 | 4/187 | 1/187 | 2/185 | 2/184 | 1/183 | 1/155 | 1/163 | 2/169 | 0/169 | 4/168 | 1/165 | 3/165 | 2/161 |
| Febrile convulsionNervous system disorders | 1/184 | 1/184 | 0/189 | 0/187 | 0/187 | 0/185 | 0/184 | 0/183 | 1/155 | 1/163 | 0/169 | 1/169 | 0/168 | 1/165 | 1/165 | 3/161 |
| LaryngitisInfections and infestations | 0/184 | 0/184 | 1/189 | 1/187 | 0/187 | 3/185 | 0/184 | 0/183 | 1/155 | 0/163 | 1/169 | 3/169 | 2/168 | 0/165 | 2/165 | 1/161 |
| Otitis media acuteInfections and infestations | 0/184 | 3/184 | 0/189 | 0/187 | 0/187 | 0/185 | 1/184 | 0/183 | 0/155 | 0/163 | 0/169 | 0/169 | 0/168 | 0/165 | 0/165 | 0/161 |
| Viral infectionInfections and infestations | 0/184 | 1/184 | 0/189 | 2/187 | 1/187 | 0/185 | 0/184 | 1/183 | 0/155 | 0/163 | 0/169 | 0/169 | 0/168 | 1/165 | 0/165 | 2/161 |
| FallInjury, poisoning and procedural complications | 0/184 | 1/184 | 0/189 | 0/187 | 0/187 | 0/185 | 0/184 | 2/183 | 0/155 | 0/163 | 2/169 | 2/169 | 0/168 | 1/165 | 0/165 | 0/161 |
| Gastroenteritis rotavirusInfections and infestations | 0/184 | 0/184 | 0/189 | 1/187 | 1/187 | 1/185 | 0/184 | 1/183 | 0/155 | 1/163 | 2/169 | 0/169 | 1/168 | 0/165 | 0/165 | 0/161 |
| BronchopneumoniaInfections and infestations | 1/184 | 0/184 | 0/189 | 1/187 | 0/187 | 0/185 | 1/184 | 2/183 | 1/155 | 0/163 | 0/169 | 0/169 | 1/168 | 0/165 | 0/165 | 0/161 |
| Respiratory syncytial virus infectionInfections and infestations | 0/184 | 0/184 | 1/189 | 0/187 | 0/187 | 0/185 | 0/184 | 2/183 | 0/155 | 0/163 | 0/169 | 0/169 | 0/168 | 0/165 | 1/165 | 0/161 |
| Event | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) | B+OMV (Group I) Booster Phase | B+½ OMV (Group II) Booster Phase | B+1/4 OMV (Group III) Booster Phase | B (Group IV) Booster Phase | ½ (B+OMV) (Group V) Booster Phase | PH2 B+OMV (Group VI) Booster Phase | MenC (Group VII) Booster Phase | Par+B+OMV (Group VIII) Booster Phase |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 157/184 | 159/184 | 155/189 | 139/187 | 151/187 | 153/185 | 121/184 | 137/183 | 116/155 | 111/163 | 112/169 | 86/169 | 116/168 | 115/165 | 126/165 | 96/161 |
| Injection site painGeneral disorders | 150/184 | 157/184 | 139/189 | 101/187 | 131/187 | 152/185 | 105/184 | 119/183 | 121/155 | 110/163 | 126/169 | 92/169 | 111/168 | 116/165 | 125/165 | 97/161 |
| Injection site erythemaGeneral disorders | 151/184 | 150/184 | 155/189 | 132/187 | 131/187 | 150/185 | 119/184 | 132/183 | 97/155 | 107/163 | 120/169 | 83/169 | 89/168 | 96/165 | 110/165 | 88/161 |
| SomnolenceNervous system disorders | 145/184 | 149/184 | 146/189 | 131/187 | 142/187 | 143/185 | 113/184 | 134/183 | 76/155 | 90/163 | 90/169 | 63/169 | 86/168 | 88/165 | 100/165 | 80/161 |
| Injection site indurationGeneral disorders | 141/184 | 139/184 | 141/189 | 126/187 | 130/187 | 130/185 | 122/184 | 126/183 | 81/155 | 90/163 | 105/169 | 71/169 | 76/168 | 81/165 | 97/165 | 70/161 |
| CryingGeneral disorders | 122/184 | 135/184 | 137/189 | 99/187 | 125/187 | 141/185 | 87/184 | 112/183 | 74/155 | 64/163 | 69/169 | 46/169 | 71/168 | 82/165 | 85/165 | 50/161 |
| PyrexiaGeneral disorders | 136/184 | 127/184 | 122/189 | 71/187 | 114/187 | 126/185 | 62/184 | 78/183 | 86/155 | 94/163 | 70/169 | 49/169 | 85/168 | 72/165 | 92/165 | 59/161 |
| Eating disorderPsychiatric disorders | 105/184 | 106/184 | 104/189 | 84/187 | 112/187 | 119/185 | 63/184 | 93/183 | 74/155 | 77/163 | 79/169 | 52/169 | 70/168 | 80/165 | 72/165 | 66/161 |
| Injection site swellingGeneral disorders | 97/184 | 94/184 | 103/189 | 80/187 | 88/187 | 100/185 | 75/184 | 77/183 | 57/155 | 63/163 | 76/169 | 46/169 | 53/168 | 57/165 | 65/165 | 50/161 |
| DiarrhoeaGastrointestinal disorders | 84/184 | 87/184 | 80/189 | 67/187 | 80/187 | 81/185 | 74/184 | 73/183 | 31/155 | 37/163 | 39/169 | 47/169 | 34/168 | 31/165 | 40/165 | 34/161 |
| Age, Categorical(Participants) | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 188 | 190 | 192 | 188 | 191 | 188 | 186 | 184 | 1507 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | B+OMV (Group I) | B+½ OMV (Group II) | B+1/4 OMV (Group III) | B (Group IV) | ½ (B+OMV) (Group V) | PH2 B+OMV (Group VI) | MenC (Group VII) | Par+B+OMV (Group VIII) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 88 | 91 | 82 | 96 | 79 | 93 | 98 | 72 | 699 |
| Male | 100 | 99 | 110 | 92 | 112 | 95 | 88 | 112 | 808 |
The record gives a start of Jul 2009, a primary completion of Nov 2010 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 4CMenB vaccine · Antipyretics